Literature DB >> 11188800

Helicobacter pylori antibiotic resistance: trends over time.

R G Lahaie1, C Gaudreau.   

Abstract

Resistance to antibiotics can be a major problem in the treatment of bacterial infections. As the use of antibiotics increases, bacterial resistance to these agents is rising and in many cases is responsible for the failure of treatment regimens. Although the treatment of Helicobacter pylori infection requires the use of more than one antibiotic to obtain adequate eradication rates, the efficacy of the currently used antibiotic combinations has been shown to be decreased by resistance to one of the antibiotics. The use of antibiotics in regiments for the treatment of H pylori is increasing in many countries, including Canada. This increase is both in the use of these antibiotics alone for the treatment of nongastrointestinal infections and in their use in association with proton pump inhibitors for the treatment of H pylori infection. In several European and Asian countries, where resistance to antibiotics is being monitored, it has been demonstrated the H pylori resistance to metronidazole and to clarithromycin increased throughout the 1990s. Thus far, the data available in Canada do not show increased resistance to either of these antibiotics. As for other antibiotics used in the treatment of H pylori infection such as tetracycline and amoxicillin, the rate of resistance to these agents is still very low and does not constitute a significant problem. Because the efficacy of the regimens used in the treatment of H pylori infection is compromised by resistance to the antibiotics used, it is important that H pylori resistance rate in Canada and throughout the world continue to be monitored. Only with such reliable data can the most optimal regimens be recommended.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11188800     DOI: 10.1155/2000/218256

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  8 in total

1.  Antibiotic susceptibility of Helicobacter pylori clinical isolates: comparative evaluation of disk-diffusion and E-test methods.

Authors:  K K Mishra; S Srivastava; A Garg; A Ayyagari
Journal:  Curr Microbiol       Date:  2006-09-12       Impact factor: 2.188

2.  Antimicrobial susceptibility of Helicobacter pylori strains isolated from patients in Shiraz, Southern Iran.

Authors:  Shohreh Farshad; Abdolvahab Alborzi; Aziz Japoni; Reza Ranjbar; Kazem Hosseini Asl; Parisa Badiee; Maneli Amin Shahidi; Marziyeh Hosseini
Journal:  World J Gastroenterol       Date:  2010-12-07       Impact factor: 5.742

Review 3.  Update on the Management of Helicobacter pylori Infection.

Authors:  Nasir Saleem; Colin W Howden
Journal:  Curr Treat Options Gastroenterol       Date:  2020-07-17

4.  Effect of bacterial flora on postimmunization gastritis following oral vaccination of mice with Helicobacter pylori heat shock protein 60.

Authors:  Hiroyuki Yamaguchi; Takako Osaki; Haruhiko Taguchi; Noriko Sato; Atushi Toyoda; Motomichi Takahashi; Masanori Kai; Noboru Nakata; Akio Komatsu; Yutaka Atomi; Shigeru Kamiya
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

5.  Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen.

Authors:  Patricia Londoño-Arcila; Donna Freeman; Harry Kleanthous; Aisling M O'Dowd; Susan Lewis; Arthur K Turner; Emma L Rees; Timothy J Tibbitts; Judith Greenwood; Thomas P Monath; Michael J Darsley
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

6.  A meta-analysis of the success rate of Helicobacter pylori therapy in Canada.

Authors:  Christopher Rodgers; Sander Veldhuyzen van Zanten
Journal:  Can J Gastroenterol       Date:  2007-05       Impact factor: 3.522

7.  Efficacy and safety of sequential versus quadruple therapy as second-line treatment for helicobacter pylori infection-A randomized controlled trial.

Authors:  Daniela Munteanu; Ohad Etzion; Gil Ben-Yakov; Daniel Halperin; Leslie Eidelman; Doron Schwartz; Victor Novack; Naim Abufreha; Pavel Krugliak; Alexander Rozenthal; Nava Gaspar; Alexander Moshkalo; Vitaly Dizingof; Alexander Fich
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240

8.  Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment: Bismuth Quadruple Therapy is Almost Always a Reasonable Choice.

Authors:  Tahir Shaikh; Carlo A Fallone
Journal:  Can J Gastroenterol Hepatol       Date:  2016-03-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.